UroGen Pharma Ltd. (NasdaqGM: URGN)
Health Care · Biotechnology · US
$46.20
-1.41% today · +141.0% 1Y
UroGen Pharma Ltd. (NasdaqGM: URGN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.29B and employs 300 people.
Over the last twelve months the share price has gained 141.0%, trading between 15.86 and 49.67.
Tweenvest scores UroGen Pharma Ltd. across four factors: quality 12/100, value 63/100, growth 91/100. Its strongest factor is growth.
URGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.29B
- Revenue (TTM)
- $188.73M
- P/E
- —
- EPS
- -1.97
- Dividend yield
- —
- Beta (5Y)
- 1.57
- 52-week high
- $49.67
- 52-week low
- $15.86
- Avg volume (3M)
- —
- Shares outstanding
- 48.88M
- Employees
- 300
- Next earnings
- —
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company’s lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
- ISIN
- IL0011407140
- Founded
- 2004
- Listed since
- May 4, 2017
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.50 | -0.55% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.25 | +0.21% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.32 | -0.55% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.33 | +0.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $825.06 | -1.08% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $135.44 | -6.64% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.